2-氨基-1-(4-溴-2,5-二甲氧基苯基)乙酮 | 807631-09-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-氨基-1-(4-溴-2,5-二甲氧基苯基)乙酮
• 英文名称: 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethan-1-one
• 英文别名: Ethanone, 2-amino-1-(4-bromo-2,5-dimethoxyphenyl)-；2-amino-1-(4-bromo-2,5-dimethoxyphenyl)ethanone
• CAS: 807631-09-0
• 化学式: C₁₀H₁₂BrNO₃
• 分子量: 274.114
• InChiKey: HFYJGAIOBIDRPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  氯甲酸-2,2,2-三氯乙酯 、 2-氨基-1-(4-溴-2,5-二甲氧基苯基)乙酮 以 乙酸乙酯 为溶剂， 反应 0.25h， 生成
  参考文献：
  名称：

  气相色谱/质谱联用和不联用2,2,2-三氯乙基氯甲酸甲酸酯的液相色谱/质谱联用表征设计药物bk-2C-B（2-氨基-1-（溴-二甲氧基苯基）乙-1-酮） /高分辨率质谱和核磁共振。

  摘要：

  理由我们描述了在没有分析标准的情况下，缉获的片剂中所含的设计药物bk-2C-B（一种卡西酮衍生物）的分析表征。方法采用的分析技术包括气相色谱/质谱法（GC / MS），无或经2,2,2-三氯乙基氯甲酸酯衍生化，液相色谱/高分辨率MS（LC / HRMS），采用Orbitrap®分析仪，和核磁共振（NMR）。LC / HRMS测量包括在完全扫描条件下对MH（+）离子物质的精确质量测量；实验和计算的MH（+）同位素模式的比较；相对于单同位素M + 0峰，检查M + 1，M + 2，M + 3同位素峰的同位素精细结构（IFS）；碎裂实验中获得的MH（+）碰撞诱导解离（CID）产物离子的研究。结果GC / MS分析给出了高度有用的EI质谱图，尤其是在bk-2C-B用2,2,2-三氯乙基氯甲酸酯衍生化之后。LC / HRMS的应用允许以100,000分辨力进行精确的质量测量，大大增强了这种新设计药物

  DOI：

  10.1002/rcm.7211

文献信息

• Methods of treating food allergy conditions
  申请人：Palo Alto Investors LP

  公开号：US11045454B2

  公开（公告）日：2021-06-29

  Methods for treating a subject for a food allergy condition are provided. Aspects of the methods include administering to a subject in need thereof a psychedelic agent in a manner effective to treat the subject for a food allergy condition. Effective administration of a psychedelic agent may include administering the psychedelic agent in an amount effective to treat the subject for the food allergy condition. In some instances, the subject is known to have a food allergy condition.

  本文提供了治疗食物过敏症的方法。这些方法的各个方面包括以有效治疗食物过敏症的方式向有需要的受试者施用迷幻剂。有效施用迷幻剂可包括以有效治疗受试者食物过敏症的量施用迷幻剂。在某些情况下，受试者已知患有食物过敏症。
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• Methods of Treating Food Allergy Conditions
  申请人：Palo Alto Investors LP

  公开号：US20200179349A1

  公开（公告）日：2020-06-11

  Methods for treating a subject for a food allergy condition are provided. Aspects of the methods include administering to a subject in need thereof a psychedelic agent in a manner effective to treat the subject for a food allergy condition. Effective administration of a psychedelic agent may include administering the psychedelic agent in an amount effective to treat the subject for the food allergy condition. In some instances, the subject is known to have a food allergy condition.
• COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
  申请人：CAAMTECH, INC.

  公开号：US20210346346A1

  公开（公告）日：2021-11-11

  Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
• [EN] COMPOSITIONS AND METHODS FOR TREATING MIGRAINE<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA MIGRAINE
  申请人：[en]WESANA HEALTH INC.

  公开号：WO2022115798A2

  公开（公告）日：2022-06-02

  As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating or preventing migraine, or symptoms thereof, with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., migraine), or symptoms thereof (e.g., anxiety or depression).